Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
502.00    -3.00 (-0.59%)
Bid:
502.00
Ask:
502.50
Spread: 0.50 (0.10%)
Market Cap: £2.22b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

9 Feb 2017 07:00

9 February 2017 – Tate & Lyle PLC

TRADING STATEMENT

Tate & Lyle issues the following trading statement for the three months ended 31 December 2016.

The Group continued to perform strongly in the third quarter with profit in constant currency ahead of the comparative period in both divisions. Speciality Food Ingredients performed in line with expectations while in Bulk Ingredients profit was ahead of our expectations.

In Speciality Food Ingredients, excluding Food Systems and SPLENDA® Sucralose, profit was ahead of the comparative period benefiting from good commercial execution and strong manufacturing performance. Underlying volume was broadly in line with the comparative period. As in the first half, demand in North America continued to be soft with volume lower, whilst in Europe, Middle East and Africa underlying volume growth was robust. Strong volume growth in Latin America largely offset weaker demand in Asia Pacific. Food Systems profit continued to be held back by lower volume and SPLENDA® Sucralose profit was ahead of the comparative period benefiting from the consolidation of production to a single facility.

In Bulk Ingredients, North American sweetener volume remained robust. The calendar 2017 bulk sweetener pricing round is now substantially complete and is expected to deliver modest margin gains in the fourth quarter. Commodities performance was satisfactory and somewhat ahead of our expectations.

Encouraged by performance in the quarter, we now expect the Group’s performance in constant currency for the full year to be modestly ahead of our expectations at the time of our Half Year Results in November 2016.

END

A conference call will be held today at 08.00am GMT, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

A replay of this call will be available after the end of the live call for 14 days until 23 February 2017.

UK replay number: +44 (0) 20 8196 1998

Replay access PIN: 7131354

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations at more than 25 facilities worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2016, Tate & Lyle sales totalled £2.4 billion. For more information, please visit http://www.tateandlyle.com.

SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170208006005/en/

Copyright Business Wire 2017

Date   Source Headline
15th May 202611:53 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
15th May 202611:35 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
15th May 202611:29 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
15th May 202611:28 amBUSForm 8.3 - TATE & LYLE PLC
15th May 202611:25 amRNSForm 8.3 - Tate & Lyle PLC
15th May 202611:20 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
15th May 202611:09 amRNSForm 8.3 - Tate & Lyle plc
15th May 202611:06 amRNS20260514_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
15th May 202611:04 amRNS20260514_TATE & LYLE_8.5 EPT RI_UK_MLI
15th May 202610:56 amRNSForm 8.3 Tate & Lyle PLC
15th May 202610:49 amPRNForm 8.3 - Tate & Lyle PLC
15th May 202610:24 amBUSDimensional Fund Advisors Ltd. : Form 8.3 - TATE & LYLE PLC - Ordinary Shares
15th May 20268:56 amRNSForm 8.5 (EPT/RI)
14th May 20264:15 pmRNSPossible 595 pence all-cash offer for Tate & Lyle
14th May 20263:25 pmRNSForm 8.3 - Tate & Lyle plc
14th May 20261:24 pmRNSDisclosure Table
14th May 20261:07 pmRNSStatement re Possible Offer for Tate & Lyle
1st May 202610:00 amRNSTotal Voting Rights
1st Apr 20264:00 pmRNSHolding(s) in Company
27th Mar 20262:00 pmRNSHolding(s) in Company
13th Mar 20264:00 pmRNSHolding(s) in Company
2nd Mar 20262:00 pmRNSHolding(s) in Company
26th Feb 20267:00 amRNSTrading Statement
23rd Feb 202610:00 amRNSHolding(s) in Company
17th Feb 202612:00 pmRNSHolding(s) in Company
21st Jan 20267:00 amRNSDirectorate change
15th Jan 20269:00 amRNSHolding(s) in Company
12th Jan 202610:00 amRNSHolding(s) in Company
7th Jan 20264:30 pmRNSDirector/PDMR Shareholding
7th Jan 20262:30 pmRNSBlock listing Interim Review
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
11th Dec 202512:18 pmRNSDirector/PDMR Shareholding
9th Dec 20259:00 amRNSHolding(s) in Company
27th Nov 202510:00 amRNSDirector/PDMR Shareholding
11th Nov 20254:30 pmRNSDirector/PDMR Shareholding
10th Nov 20252:40 pmRNSDirector Declaration
6th Nov 20257:00 amRNSHalf-year Financial Report
5th Nov 20252:15 pmRNSHolding(s) in Company
3rd Nov 20255:00 pmRNSHolding(s) in Company
29th Oct 20252:00 pmRNSHolding(s) in Company
23rd Oct 20254:15 pmRNSHolding(s) in Company
21st Oct 20253:30 pmRNSHolding(s) in Company
16th Oct 202512:00 pmRNSHolding(s) in Company
8th Oct 202512:00 pmRNSHolding(s) in Company
6th Oct 20254:30 pmRNSDirector/PDMR Shareholding
6th Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 202510:00 amRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSPre-close statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.